Your prior IC analysis is way off.
The trial as a whole had 31% treated with a CI in 1st line, In the trial SOC is physicians choice of chemo or CI. As is normal doctors rarely used CI if it had already failed. Thus only 2 % of patents who used 2nd line CI (the trial) had used it front line.
As far as "99%", nonsense. The label for front line is only for those with greater than 50% PD-1 expression or metastatic.
The news was bad (relatively), but I doubt you would know why,